Drug discovery company Argent BioPharma (ASX: RGT) (LSE: RGT) (OTCQB: RGTLF) on Monday announced a strategic collaboration with SINTEF, a large European independent research organisation, to tackle the clinical challenge of chronic wound management.

This partnership aims to develop nano-formulations that address antibiotic-resistant infections and deteriorating tissue health, marking Argent BioPharma's expansion into new therapeutic areas.

The collaboration will focus on identifying novel antimicrobial agents and enhancing their effectiveness through nano-formulation technology. These formulations are designed to improve drug delivery, penetrate biofilms and provide sustained release, addressing the complexities of chronic wounds.

Argent BioPharma will fund the project and retain ownership of all intellectual property generated.

This initiative aligns with Argent BioPharma's broader strategy of developing multidisciplinary, nano-based therapies, particularly in the central nervous system and immunology sectors.